Biora Therapeutics Home
Activate the mobile navigation
Close the mobile navigation Close
Home
  • Company
    • About
    • Quality
    • Careers
  • Platforms
    • BioJet Oral Therapeutic Delivery
    • NaviCap Targeted Therapeutic Delivery
  • Publications
  • News
    • Press Releases
    • Investor FAQs
  • Contact
Toggle the search bar
Close the mobile navigation

Publications

Development of a novel drug delivery system to deliver drugs directly to the colonic mucosa
July 7, 2021 #NaviCap Targeted Therapeutic Delivery
Development of a novel drug delivery system for targeted treatment of ulcerative colitis
May 20, 2021 #NaviCap Targeted Therapeutic Delivery
Targeted delivery of tofacitinib citrate to the site of disease to improve efficacy and safety
May 20, 2021 #NaviCap Targeted Therapeutic Delivery
Targeted topical anti-α4β7 integrin antibody results in reduced accumulation of α4β7 memory T-cells in gut tissue in DSS-induced colitis mice
October 28, 2019 #NaviCap Targeted Therapeutic Delivery
1 2

Connect with us

Email Us Biora Therapeutics Linkedin Biora Therapeutics Twitter
  • Company

    About Quality Careers

    Platforms

    BioJet Oral Therapeutic Delivery NaviCap Targeted Therapeutic Delivery
  • Publications

    BioJet Publications NaviCap Publications
  • Connect with Us

    Contact Us
    Email Us Biora Therapeutics Linkedin Biora Therapeutics Twitter
Privacy & Terms of Use Accessibility

© 2025 Biora Therapeutics, Inc. All rights reserved. Biora Therapeutics, NaviCap, BioJet, and GITrac are trademarks of Biora Therapeutics, Inc.

Precaution: investigational drug/device combination products. Currently limited by Federal law to investigational use only. Not for sale in the U.S.